Tower Research Capital LLC (Trc) Travere Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 21,367 shares of TVTX stock, worth $457,253. This represents 0.01% of its overall portfolio holdings.
Number of Shares
21,367
Previous 6,866
211.2%
Holding current value
$457,253
Previous $96,000
287.5%
% of portfolio
0.01%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding TVTX
# of Institutions
214Shares Held
94.3MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$164 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$157 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$144 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$106 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$91.2 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.37B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...